Guggenheim Capital LLC Regenxbio Inc. Transaction History

Guggenheim Capital LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$20.4 - $24.73 $190,597 - $231,052	9,343 New	9,343 $211,000
Q3 2021 Nov 15, 2021	SELL	$29.09 - $45.68 $157,638 - $247,539	-5,419 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$32.46 - $40.48 $17,755 - $22,142	-547 Reduced 9.17%	5,419 $211,000
Q1 2021 May 13, 2021	SELL	$33.61 - $49.95 $188,552 - $280,219	-5,610 Reduced 48.46%	5,966 $204,000
Q4 2020 Feb 16, 2021	BUY	$26.52 - $49.35 $306,995 - $571,275	11,576 New	11,576 $525,000
Q4 2019 Feb 14, 2020	SELL	$34.54 - $44.87 $1.49 Million - $1.94 Million	-43,125 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$31.84 - $50.88 $53,491 - $85,478	1,680 Added 4.05%	43,125 $1.54 Million
Q2 2019 Aug 14, 2019	SELL	$42.0 - $59.29 $132,300 - $186,763	-3,150 Reduced 7.06%	41,445 $2.13 Million
Q1 2019 May 15, 2019	BUY	$40.82 - $62.45 $87,313 - $133,580	2,139 Added 5.04%	44,595 $2.56 Million
Q4 2018 Feb 14, 2019	BUY	$39.11 - $75.15 $1.66 Million - $3.19 Million	42,456 New	42,456 $1.78 Million

193

43.5M

58.9K

58.4K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $404M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.